Summary
Elevance Health, Inc. (ELV) announced on May 29, 2024, the closing of a significant notes offering, raising approximately $2.57 billion in net proceeds. This offering included $600 million in 5.150% Notes due 2029, $1 billion in 5.375% Notes due 2034, and $1 billion in 5.650% Notes due 2054. The company intends to use these funds for general corporate purposes, including working capital, potential acquisitions, debt repayment, and share repurchases. This financing action provides Elevance Health with substantial liquidity to support its strategic initiatives and financial flexibility. Investors should note the specific interest rates and maturity dates associated with each tranche of notes, as well as the terms for redemption and potential change of control provisions that could trigger an accelerated repurchase of the notes. The company's ability to continue incurring debt under the indenture provides further operational flexibility.
Key Highlights
- 1Closed a notes offering totaling $2.57 billion in net proceeds.
- 2Issued three tranches of senior unsecured notes: $600M (5.150% due 2029), $1B (5.375% due 2034), and $1B (5.650% due 2054).
- 3Net proceeds will be used for general corporate purposes, including working capital, acquisitions, debt repayment, and share repurchases.
- 4The indenture does not restrict the incurrence of additional indebtedness by the company or its subsidiaries.
- 5Notes are subject to optional redemption by the company prior to maturity, with specific call protection periods.
- 6A change of control event coupled with a credit rating downgrade could trigger a mandatory offer to purchase the notes at 101% of principal.